SANTA CRUZ BIOTECHNOLOGY, INC.

KIAA1704 (N-15): sc-84511



BACKGROUND

KIAA1704, also known as LSR7 (lipopolysaccharide-specific response protein 7), is a 340 amino acid protein that is encoded by a gene which maps to chromosome 13. Comprising nearly 4% of human DNA, chromosome 13 contains around 114 million base pairs and 400 genes. Key tumor suppressor genes on chromosome 13 include the breast cancer susceptibility gene, BRCA2, and the RB1 (retinoblastoma) gene. RB1 encodes a crucial tumor suppressor protein which, when defective, leads to malignant growth in the retina and has been implicated in a variety of other cancers. As with most chromosomes, polysomy of part or all of chromosome 13 is deleterious to development and decreases the odds of survival. Trisomy 13, also known as Patau syndrome, is quite deadly and the few who survive past one year suffer from permanent neurologic defects, difficulty eating and vulnerability to serious respiratory infections. There are four isoforms of KIAA1704 that are produced as a result of alternative splicing events.

REFERENCES

- Nagase, T., Kikuno, R., Hattori, A., Kondo, Y., Okumura, K. and Ohara, O. 2000. Prediction of the coding sequences of unidentified human genes. XIX. The complete sequences of 100 new cDNA clones from brain which code for large proteins *in vitro*. DNA Res. 7: 347-355.
- Dunham, A., Matthews, L.H., Burton, J., Ashurst, J.L., Howe, K.L., Ashcroft, K.J., Beare, D.M., Burford, D.C., Hunt, S.E., Griffiths-Jones, S., Jones, M.C., Keenan, S.J., Oliver, K, et al. 2004. The DNA sequence and analysis of human chromosome 13. Nature 428: 522-528.
- Deng, H., Le, W.D., Xie, W.J. and Jankovic, J. 2006. Examination of the SLITRK1 gene in Caucasian patients with Tourette syndrome. Acta Neurol. Scand. 114: 400-402.
- 4. Giacinti, C. and Giordano, A. 2006. RB and cell cycle progression. Oncogene 25: 5220-5227.
- Grados, M.A. and Walkup, J.T. 2006. A new gene for Tourette's syndrome: a window into causal mechanisms? Trends Genet. 22: 291-293.
- Bugge, M., Collins, A., Hertz, J.M., Eiberg, H., Lundsteen, C., Brandt, C.A., Bak, M., Hansen, C., Delozier, C.D., Lespinasse, J., Tranebjaerg, L., Hahnemann, J.M., Rasmussen, K., Bruun-Petersen, G., Duprez, L., Tommerup, N. and Petersen, M.B. 2007. Non-disjunction of chromosome 13. Hum. Mol. Genet. 16: 2004-2010.
- Hsu, H.F. and Hou, J.W. 2007. Variable expressivity in Patau syndrome is not all related to trisomy 13 mosaicism. Am. J. Med. Genet. A 143: 1739-1748.
- Hall, H.E., Chan, E.R., Collins, A., Judis, L., Shirley, S., Surti, U., Hoffner, L., Cockwell, A.E., Jacobs, P.A. and Hassold, T.J. 2007. The origin of trisomy 13. Am. J. Med. Genet. A 143: 2242-2248.
- Hassler, M., Singh, S., Yue, W.W., Luczynski, M., Lakbir, R., Sanchez-Sanchez, F., Bader, T., Pearl, L.H. and Mittnacht, S. 2007. Crystal structure of the retinoblastoma protein N domain provides insight into tumor suppression, ligand interaction and holoprotein architecture. Mol. Cell 28: 371-385.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

CHROMOSOMAL LOCATION

Genetic locus: KIAA1704 (human) mapping to 13q14.12; 1200011118Rik (mouse) mapping to 14 D3.

SOURCE

KIAA1704 (N-15) is an affinity purified rabbit polyclonal antibody raised against a peptide mapping at the N-terminus of KIAA1704 of human origin.

PRODUCT

Each vial contains 100 μg lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-84511 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

KIAA1704 (N-15) is recommended for detection of KIAA1704 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with isoforms 2 and 3.

KIAA1704 (N-15) is also recommended for detection of KIAA1704 in additional species, including equine, canine, bovine, porcine and avian.

Suitable for use as control antibody for KIAA1704 siRNA (h): sc-75717, KIAA1704 siRNA (m): sc-108207, KIAA1704 shRNA Plasmid (h): sc-75717-SH, KIAA1704 shRNA Plasmid (m): sc-108207-SH, KIAA1704 shRNA (h) Lentiviral Particles: sc-75717-V and KIAA1704 shRNA (m) Lentiviral Particles: sc-108207-V.

Molecular Weight of KIAA1704: 38 kDa.

STORAGE

Store at 4° C, **D0 NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.